Published in J Hematol Oncol on August 12, 2009
Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther (2010) 2.38
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood (2010) 2.01
Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst (2011) 1.86
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. Blood (2011) 1.84
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma (2012) 1.47
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood (2011) 1.44
Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited. Adv Hematol (2012) 1.24
Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res (2013) 1.22
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer (2011) 1.19
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol (2010) 1.18
Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol (2011) 1.06
Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol (2011) 1.02
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J (2013) 1.01
Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol (2012) 1.01
Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol (2012) 1.00
IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia (2011) 0.98
Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol (2012) 0.98
Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood (2015) 0.97
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2014) 0.96
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
Retinoid differentiation therapy for common types of acute myeloid leukemia. Leuk Res Treatment (2012) 0.94
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol (2015) 0.94
Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol (2010) 0.94
Diamond Blackfan anemia treatment: past, present, and future. Semin Hematol (2011) 0.90
Clinical trials with anti-angiogenic agents in hematological malignancies. J Angiogenes Res (2010) 0.90
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood (2011) 0.90
New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clin Cancer Res (2011) 0.90
Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol (2011) 0.89
Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap. Eur J Nucl Med Mol Imaging (2015) 0.88
Nitric oxide rescues thalidomide mediated teratogenicity. Sci Rep (2012) 0.88
Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS One (2011) 0.86
Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int (2014) 0.86
Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res (2012) 0.84
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. J Neuroinflammation (2015) 0.84
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk (2012) 0.83
Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs. J Virol (2012) 0.83
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther Adv Hematol (2011) 0.82
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica (2014) 0.82
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date. Onco Targets Ther (2016) 0.81
Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells. Oncol Lett (2012) 0.80
Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. Mol Cancer Ther (2015) 0.79
Novel agents in indolent lymphomas. Ther Adv Hematol (2013) 0.79
Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. Exp Neurol (2015) 0.79
Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma. Ther Adv Drug Saf (2012) 0.78
Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus. Adv Hematol (2012) 0.78
Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas. Adv Hematol (2012) 0.78
Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs. Proc Natl Acad Sci U S A (2015) 0.78
Microenvironment-a role in tumour progression and prognosis. J Clin Diagn Res (2013) 0.77
Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions. Drugs (2015) 0.77
Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma. Clin Med Insights Oncol (2011) 0.76
Treatment of Cancer Pain by Targeting Cytokines. Mediators Inflamm (2015) 0.76
Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3(+)CD8(+) T cells against Various Solid Tumors. J Leuk (Los Angel) (2015) 0.76
Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies. J Adv Pract Oncol (2015) 0.76
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors. Invest New Drugs (2011) 0.76
Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients. Onco Targets Ther (2015) 0.75
The emerging role of lenalidomide in the management of lymphoid malignancies. Ther Adv Hematol (2011) 0.75
Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand. J Hematol Oncol (2010) 0.75
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. J Blood Med (2014) 0.75
Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma. P T (2016) 0.75
Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation. Ecancermedicalscience (2013) 0.75
Dramatic response in the dependency to transfusion after low doses of lenalidomide treatment in a 5q-syndrome patient: a case report. North Clin Istanb (2015) 0.75
Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.75
Successful control of acute myelofibrosis with lenalidomide. Case Rep Med (2011) 0.75
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma. Ther Adv Hematol (2016) 0.75
Lenalidomide-induced eosinophilic pneumonia. Respirol Case Rep (2017) 0.75
Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathol Commun (2017) 0.75
Lenalidomide-induced acute interstitial nephritis. Oncologist (2010) 0.75
New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals. Discoveries (Craiova) (2015) 0.75
Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia. Mediterr J Hematol Infect Dis (2010) 0.75
Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med (2005) 8.80
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med (2006) 8.16
Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A (1994) 6.48
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol (1999) 3.99
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol (2006) 3.95
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 3.89
The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer (2004) 3.58
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med (1993) 3.31
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01
T-cell costimulation--biology, therapeutic potential, and challenges. N Engl J Med (2006) 2.81
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol (2008) 2.80
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood (2007) 2.80
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res (2008) 2.79
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A (2007) 2.39
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood (2003) 2.22
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol (2007) 2.14
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer (2002) 2.03
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol (2005) 1.99
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med (2008) 1.97
Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood (2006) 1.97
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood (2006) 1.94
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia (2004) 1.90
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A (2009) 1.83
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res (2007) 1.74
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem (2007) 1.65
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol (2007) 1.64
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett (1999) 1.62
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol (2009) 1.57
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia (2008) 1.56
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res (2005) 1.52
The thalidomide saga. Int J Biochem Cell Biol (2007) 1.39
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol (2002) 1.35
Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol (1995) 1.35
Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J (2005) 1.33
Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology (1996) 1.26
Thalidomide--effect on T cell subsets as a possible mechanism of action. Int J Lepr Other Mycobact Dis (1985) 1.24
Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol (2006) 1.24
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res (2006) 1.17
Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle (2008) 1.17
Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia (2007) 1.16
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res (2007) 1.09
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer (2006) 1.02
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer (2006) 0.98
Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol (2008) 0.98
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. Clin J Oncol Nurs (2007) 0.96
Phase I study of lenalidomide in solid tumors. J Thorac Oncol (2007) 0.96
Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control (2006) 0.95
Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand J Immunol (1981) 0.91
Recent advances in the therapy of renal cancer. Expert Opin Biol Ther (2007) 0.89
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol (2006) 0.89
Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur J Haematol (1991) 0.87
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. Invest New Drugs (2006) 0.86
Recent advances in myelodysplastic syndromes. Exp Hematol (2007) 0.85
Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. Gynecol Oncol (2007) 0.83
Thalidomide: a novel template for anticancer drugs. Semin Oncol (2001) 0.79
Lenalidomide: from bench to bedside (part 1). Cancer Control (2006) 0.79
Cytosine methylation dysregulation in neonates following intrauterine growth restriction. PLoS One (2010) 2.10
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood (2012) 1.98
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood (2008) 1.95
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
Arsenic contamination in groundwater: a global perspective with emphasis on the Asian scenario. J Health Popul Nutr (2006) 1.81
High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res (2009) 1.80
Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem (2002) 1.72
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica (2012) 1.53
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood (2010) 1.53
Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biol (2013) 1.52
Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology (2013) 1.49
Outcome from therapeutic hypothermia and EEG. J Clin Neurophysiol (2011) 1.48
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood (2006) 1.48
Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet (2011) 1.47
Cancer biomarkers - current perspectives. Indian J Med Res (2010) 1.44
Primary care physicians' awareness, experience and opinions of direct-to-consumer genetic testing. J Genet Couns (2011) 1.42
Avoiding tracheostomy: submental intubation in faciomaxillary trauma surgery. Plast Reconstr Surg (2004) 1.39
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood (2009) 1.37
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood (2012) 1.36
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood (2012) 1.33
Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. Nat Immunol (2013) 1.28
Activation of protein kinase C delta by IFN-gamma. J Immunol (2003) 1.25
Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J Immunol (2008) 1.22
Status of groundwater arsenic contamination in Bangladesh: a 14-year study report. Water Res (2010) 1.20
Status of groundwater arsenic contamination in the state of West Bengal, India: a 20-year study report. Mol Nutr Food Res (2009) 1.20
Osteopontin regulates actin cytoskeleton and contributes to cell proliferation in primary erythroblasts. J Biol Chem (2008) 1.16
Improvement in β-cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes (2013) 1.15
Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci U S A (2003) 1.14
Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res (2005) 1.13
Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes Cancer (2010) 1.12
Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma (2008) 1.11
Novel nanostructured rare-earth-free magnetic materials with high energy products. Adv Mater (2013) 1.11
Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res (2010) 1.10
miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood (2013) 1.08
Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol (2013) 1.07
Activation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem (2003) 1.06
Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res (2007) 1.06
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood (2002) 1.06
Arsenic groundwater contamination and its health effects in the state of Uttar Pradesh (UP) in upper and middle Ganga plain, India: a severe danger. Sci Total Environ (2006) 1.05
Tissue transglutaminase promotes or suppresses tumors depending on cell context. Anticancer Res (2009) 1.04
Aberrant DNA methylation in malignant melanoma. Melanoma Res (2010) 1.04
DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med (2010) 1.03
High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci (2007) 1.03
A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol (2011) 1.03
Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem (2004) 1.02
p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure. Cell Cycle (2007) 1.02
Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors. Am J Hematol (2009) 1.01
In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol Pharmacol (2011) 1.01
Educational needs of primary care physicians regarding direct-to-consumer genetic testing. J Genet Couns (2011) 1.00
Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Nucleic Acids Res (2013) 1.00
Vision problems, eye care history, and ocular protection among migrant farmworkers. Arch Environ Occup Health (2008) 1.00
Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood (2012) 0.99
Alterations in the ribosomal machinery in cancer and hematologic disorders. J Hematol Oncol (2012) 0.97
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem (2011) 0.97
Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration. PLoS One (2008) 0.96
Low-dose radiation therapy of cancer: role of immune enhancement. Expert Rev Anticancer Ther (2011) 0.96
Signal transduction inhibitors in treatment of myelodysplastic syndromes. J Hematol Oncol (2013) 0.95
Novel retinoic acid receptor alpha agonists for treatment of kidney disease. PLoS One (2011) 0.95
Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y) (2013) 0.94
An eight-year study report on arsenic contamination in groundwater and health effects in Eruani village, Bangladesh and an approach for its mitigation. J Health Popul Nutr (2006) 0.93
Murshidabad--one of the nine groundwater arsenic-affected districts of West Bengal, India. Part II: dermatological, neurological, and obstetric findings. Clin Toxicol (Phila) (2005) 0.93
T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia. J Immunol (2013) 0.92
Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Int J Clin Exp Pathol (2012) 0.92
Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer Res (2012) 0.92
Arsenic burden from cooked rice in the populations of arsenic affected and nonaffected areas and Kolkata City in West-Bengal, India. Environ Sci Technol (2009) 0.91
Green tobacco sickness and skin integrity among migrant Latino farmworkers. Am J Ind Med (2008) 0.91
High resolution methylome analysis reveals widespread functional hypomethylation during adult human erythropoiesis. J Biol Chem (2013) 0.91
Status of groundwater arsenic contamination and human suffering in a Gram Panchayet (cluster of villages) in Murshidabad, one of the nine arsenic affected districts in West Bengal, India. J Water Health (2005) 0.89
Self report of skin problems among farmworkers in North Carolina. Am J Ind Med (2008) 0.89
Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica (2014) 0.89
Essential role for B cells in transplantation tolerance. Curr Opin Immunol (2011) 0.89
Curcumin inhibits Rift Valley fever virus replication in human cells. J Biol Chem (2012) 0.89
Ineffectiveness and poor reliability of arsenic removal plants in West Bengal, India. Environ Sci Technol (2005) 0.89
Complex limbal choristoma in nevus sebaceous syndrome. Pediatr Dermatol (2012) 0.89
Additional danger of arsenic exposure through inhalation from burning of cow dung cakes laced with arsenic as a fuel in arsenic affected villages in Ganga-Meghna-Brahmaputra plain. J Environ Monit (2007) 0.88
Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma. Ann N Y Acad Sci (2013) 0.88
HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. J Clin Invest (2014) 0.88
The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. Int J Dermatol (2009) 0.88
Imaging devices for use in small animals. Semin Nucl Med (2011) 0.87
Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling. J Biol Chem (2010) 0.87
Kinase inhibitors translate lab discoveries into exciting new cures for cancers. Indian J Pediatr (2004) 0.87
Giant atypical carcinoid of the liver with vascular metastases and local sinusoidal invasion: a case report. J Med Case Rep (2007) 0.87
Examining India's groundwater quality management. Environ Sci Technol (2010) 0.87
Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF. Transplantation (2012) 0.86
An uncommon case of an adult with del(5)(q) in acute lymphoblastic leukemia. Indian J Hum Genet (2012) 0.86
Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors. J Biol Chem (2013) 0.84
Signalling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Leuk Lymphoma (2004) 0.84
Murshidabad--one of the nine groundwater arsenic-affected districts of West Bengal, India. Part I: magnitude of contamination and population at risk. Clin Toxicol (Phila) (2005) 0.84
AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation. Cancer Res (2004) 0.83
Magnetic resonance imaging changes in a case of extra-pyramidal syndrome after acute organophosphate poisoning. Neurol India (2006) 0.83
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. J Clin Oncol (2013) 0.83
Underutilization of A2 ABO incompatible kidney transplantation. Clin Transplant (2011) 0.83